Acumen Pharmaceuticals (ABOS) Amortization of Deferred Charges (2022 - 2026)
Acumen Pharmaceuticals (ABOS) reported Amortization of Deferred Charges of $34000.0 for Q1 2026, up 13.33% on a YoY basis from $30000.0 in Q1 2025, and up 3.03% sequentially from $33000.0 in Q4 2025.
Acumen Pharmaceuticals (ABOS) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 5 years of Amortization of Deferred Charges data on file, last reported at $34000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 13.33% year-over-year to $34000.0; the trailing twelve-month figure through Mar 2026 stood at $130000.0 (up 11.11% YoY), and the FY2025 full-year result was $126000.0, up 9.57% from the prior year.
- Amortization of Deferred Charges climbed to $34000.0 in Q1 2026, from $33000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $38000.0 in Q1 2023 to a low of $20000.0 in Q4 2023.
- A 5-year average of $31470.6 and a median of $32000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges sank 45.95% in 2023 and jumped 50.0% in 2024, its largest moves.
- Tracing ABOS's Amortization of Deferred Charges over 5 years: stood at $37000.0 in 2022, then tumbled by 45.95% to $20000.0 in 2023, then jumped by 50.0% to $30000.0 in 2024, then rose by 10.0% to $33000.0 in 2025, then grew by 3.03% to $34000.0 in 2026.
- Business Quant data shows ABOS's Amortization of Deferred Charges at $34000.0 in Q1 2026, $33000.0 in Q4 2025, and $32000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn |
| 10 | Acumen Pharmaceuticals | 140.66 Mn | 140.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Dec 31, 2023 | 20,000.00 |